ACM
EWTX icon

ADAR1 Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

ADAR1 Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.85M Sell
90,599
-400
-0.4% -$11.5K 0.17% 110
2025
Q4 		$2.26M Buy
90,999
+50,999
+127% +$1.02M 0.17% 95
2025
Q3 		$649K Hold
40,000
– – 0.06% 123
2025
Q2 		$524K Buy
40,000
+20,000
+100% +$288K 0.08% 115
2025
Q1 		$440K Buy
+20,000
New +$525K 0.08% 113
2024
Q4 		– Sell
-18,178
Closed -$485K – 244
2024
Q3 		$485K Sell
18,178
-418,430
-96% -$8.32M 0.08% 119
2024
Q2 		$7.86M Buy
436,608
+255,697
+141% +$4.46M 1.48% 15
2024
Q1 		$3.3M Buy
+180,911
New +$2.88M 0.75% 24

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ADAR1 Capital Management's EWTX Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 0.44% in Q1 2026, selling an estimated $11.5K and leaving 90,599 shares worth $2.85M. The position accounts for 0.17% of the portfolio, ranked #110.

ADAR1 Capital Management first reported a position in EWTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.86M in Q2 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • ADAR1 Capital Management held 90,599 shares of Edgewise Therapeutics worth $2.85M as of Q1 2026.
  • ADAR1 Capital Management sold 400 Edgewise Therapeutics shares in Q1 2026, an estimated $11.5K.
  • Edgewise Therapeutics made up 0.17% of ADAR1 Capital Management's portfolio in Q1 2026, its #110 holding.
  • ADAR1 Capital Management first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • ADAR1 Capital Management's Edgewise Therapeutics position peaked at $7.86M in Q2 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.